NBTXR-3 is under clinical development by Janssen Pharmaceuticals and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NBTXR-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NBTXR-3 overview
NBTXR-3 is under development for the treatment of head and neck cancer squamous cell carcinoma, recurrent head and neck cancer squamous cell carcinoma, soft tissue sarcoma, esophageal cancer, pancreatic ductal adenocarcinoma, esophageal adenocarcinoma, pancreatic cancer, hepatocellular carcinoma, melanoma, renal cell carcinoma, transitional cell cancer (urothelial cell cancer), cervical cancer, triple-negative breast cancer (TNBC), metastatic liver cancer, non-small cell lung cancer, squamous cell carcinoma (SCC) of the oral cavity or oropharynx, laryngeal cancer and hypopharyngeal cancer and solid tumor. It is administered through intratumoral route. The therapeutic candidate is composed of functionalized hafnium oxide nanoparticles. It was also under development for rectal cancer. The drug candidate is a radiation sensitizer.
Janssen Pharmaceuticals overview
Janssen Pharmaceuticals (Janssen), a subsidiary of Johnson & Johnson, develops and supplies prescription pharmaceutical products. It offers all types of medicines such as tablets, nasal sprays, oral solutions, injections, capsules, vaccines, and creams for an array of health conditions in therapeutic areas of cardiovascular and metabolism; infectious diseases and vaccines, neuroscience, immunology, oncology, and pulmonary hypertension. The company offers products under the brand names of Balversa, Sirturo, Ventavis, Concerta, Uptravi, Darzalex Faspro, Darzalex, Elmiron, Prezista, Haldol, Rybrevant, Invokana, Intelence, Zytiga, and Tracleer. Janssen markets its products through a network of distributors across the US. Janssen is headquartered in Titusville, New Jersey, the US.
For a complete picture of NBTXR-3’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
